Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Net Income (2016 - 2025)

Regenxbio has reported Net Income over the past 12 years, most recently at -$67.2 million for Q4 2025.

  • Quarterly results put Net Income at -$67.2 million for Q4 2025, down 31.01% from a year ago — trailing twelve months through Dec 2025 was -$194.0 million (up 14.66% YoY), and the annual figure for FY2025 was -$194.0 million, up 14.59%.
  • Net Income for Q4 2025 was -$67.2 million at Regenxbio, down from -$62.0 million in the prior quarter.
  • Over the last five years, Net Income for RGNX hit a ceiling of $294.0 million in Q4 2021 and a floor of -$76.7 million in Q1 2022.
  • Median Net Income over the past 5 years was -$61.9 million (2023), compared with a mean of -$27.8 million.
  • Peak annual rise in Net Income hit 392.34% in 2021, while the deepest fall reached 764.37% in 2021.
  • Regenxbio's Net Income stood at $294.0 million in 2021, then dropped by 25.04% to $220.4 million in 2022, then tumbled by 128.57% to -$63.0 million in 2023, then increased by 18.58% to -$51.3 million in 2024, then tumbled by 31.01% to -$67.2 million in 2025.
  • The last three reported values for Net Income were -$67.2 million (Q4 2025), -$62.0 million (Q3 2025), and -$70.9 million (Q2 2025) per Business Quant data.